The introduction of drug-eluting stents (DES) has rapidly and profoundly affected the field of interventional cardiology, and DESs are now used in a majority of intracoronary stenting procedures. As a result of the innumerable "trial-and-error" endeavors, DESs have emerged as a potential solution for solving the problem of restenosis. DESs are coated stents capable of releasing single or multiple bioactive agents into the bloodstream and the surrounding tissues. The efficacy and safety of DESs might differ depending on the pharmacologic agents and stent delivery systems that are used. Recent research has focused on the various constituents of DESs, including the stent backbone, the materials used as drug-delivery vehicles, and the physicochemical properties of the pharmacotherapeutic agents themselves. Stent-induced mechanical arterial injury and a foreign body response to the prosthesis incite acute and chronic inflammation in the vessel wall, along with the elaboration of cytokines and growth factors that induce multiple signaling pathways to activate smooth muscle cell migration and proliferation. Utilization of antiproliferative agents delivered locally via the drug-eluting stents has dramatically reduced the stent restenosis rate. The polymer-regulated delivery of both paclitaxel and sirolimus at the site of arterial injury has been shown to reduce the clinical and angiographic restenosis rates after stent implantation in de novo coronary lesion. Other DESs have yielded somewhat less brilliant results or even true failures, while a number of new drugs and new stent platforms are now under clinical or preclinical evaluation. In this review, we describe the main clinical trials on DESs and the most recent information that has been derived from observational studies and registries. Moreover, the preliminary results on the new DESs are also summarized. (Korean Circulation J 2005 ; 35 : 197-205) KEY WORDS：Coronary disease；Stents；Restenosis.
Introduction
Although several studies have indicated overwhelmingly positive results with using stent-based drug delivery for the prevention of restenosis, 1) 2) and early clinical trials of several agents have also seemed promising, larger studies with longerterm follow-up have subsequently led to the conclusion that the efficacy and safety might differ among the pharmacologic agents and among the stent delivery systems. Consequently, the research focus has been directed toward the various constituents of drug-delivery stents, which include the stent backbone, the materials used as drug-delivery vehicles, and the physicochemical properties of the pharmacotherapeutic agents themselves. The concept of using stents as vehicles for the prolonged and sufficient intramural delivery of drugs is appealing. Stents represent an ideal platform for local drug delivery because of their permanent scaffolding properties that prevent vessel recoil and negative remodeling. In addition, the stents represent drug reservoirs, inasmuch as medications are released from various coatings at different time intervals.
In principle, most of the DES technologies face many potential limitations (Table 1) . 3) Future generations of drug-delivery stents will require each of these above parameters to be optimized to provide the greatest possible efficacy and safety. Although a specific targeted mechanism of action is an important consideration, many agents have been demonstrated to have multiple mechanisms by which they might suppress the restenotic process.
Based on the mechanism of action of the biological compound and its target in the restenotic process, drug-eluting stents(DES) may be generally classified into the immunosuppressive, antiproliferative, antiinflammatory, antithrombotic and prohealing stents. These types of DESs are summarized on Table 2 .
4)

Stents eluting antiinflammatory agents
There is increasing evidence that inflammation plays an important role in the initiation and development of neoint-imal hyperplasia and the subsequent restenosis. Because of their role in restenosis, inflammatory cells seemed to be an optimal target in the fight against restenosis.
Corticosteroid-eluting stents
Indeed, corticosteroids have long been known to reduce the influx of mononuclear cells, to inhibit monocyte and macrophage function, and to influence smooth muscle cell proliferation. 5) However, the data that is available on the utility of antiinflammatory DESs is limited. 8)
The anti-inflammatory effects of tranilast have been demonstrated for the inhibition of prostaglandin E 2 , thromboxane B 2 , transforming growth factor-β 1 and interleukin-8 in in vitro models, and tranilast has also shown it ability to attenuate the proinflammatory activity of human monocytes. 8) Further, 
Stents eluting immunosuppressive agents
Encouraged by the early experience with ionizing radiation therapy, researchers have proposed sophisticated pharmacological strategies for interfering with cell cycle division. effect of everolimus when it is given orally or via a DES.
13)
The S-Stent(Biosensor) has been impregnated with a blend of everolimus and a slowly biodegradable hydroxyacid polylactic acid polymer.
The First Use To Underscore Reduction in restenosis with everolimus(FUTURE) study 14) was the first human evaluation of the everolimus-eluting stent(EES) for the treatment of noncomplex coronary lesions. Forty-two patients with de novo coronary lesions(2.75 to 4.00 mm vessels; lesion length: <18 mm) were prospectively randomized in a 2:1 ratio to receive either the EES(n=27) or a metallic stent(n=15). At the 6-month follow-up, the EES had a lower in-stent late lumen loss(0.10±0.22 vs 0.85±0.32 mm, respectively, p< 0.0001) and a lower in-segment diameter stenosis(20.7±
12.3% vs 37.0±15.8 respectively), than the metallic stent.
In the second feasibility trial that included diabetics, the multicenter trial FUTURE II confirmed the initial beneficial findings of FUTURE I in a total study population of 64 patients with a 1: 2 randomization for comparing with a bare metal control stent. Based on these results, the FUTURE program has now been expanded by Guidant with two largescale multicenter studies, FUTURE III and IV, which will evaluate this stent design in a larger patient population. Furthermore, the FUTURE IV study is planned to demonstrate the non-inferiority of this stent concept in a head-to-head comparison with an approved DES concept.
ABT-578(methyl rapamycin) is a new synthetic analog of rapamycin that is designed to inhibit smooth muscle cell proliferation, which is a key contributor to restenosis, by blocking the function of the mTOR cell cycle regulatory protein. Given these pharmacodynamics, ABT-578 was considered beneficial for intracoronary delivery to arrest the processes responsible for neointimal hyperplasia after angioplasty and stenting.
Consequently, the ABT-578-eluting ENDEAVOR stent system has been created, and it represents a potential new alternative for treating patients with coronary heart disease.
In order to evaluate the safety, feasibility and efficacy of 
FK506(Tacrolimus)-eluting stents
Tacrolimus is a hydrophobic immunosuppressive agent that has been used clinically to prevent renal transplant rejection. 
Stents eluting antiproliferative agents
A number of antineoplastic medications have been considered for the prevention of restenosis. Paclitaxel and its derivatives are the most investigated compounds of this medication group.
Angiopeptin-eluting stents
Somatostatin, an angiopeptin analogue, has been shown to reduce tissue response to several growth factors, including platelet-derived growth factor, basic fibroblast and insulinlike growth factors. In humans, the systemic administration of angiopeptin improved the clinical outcome after angioplasty, but it showed no effect on restenosis.
17)
Armstrong et al. 18) The in-stent late lumen loss and that at the proximal and distal edges were higher in both DES groups than in the MS group, and this resulted in higher six-month and one-year MACE(34.8% and 43.1% vs. 13.5%, respectively), and these findings were exclusively driven by the target vessel revascularization without excess death or myocardial infarction.
So, the researchers concluded that all anti-proliferative drugs will not uniformly show a drug class effect for the prevention of restenosis.
C-myc antisense-eluting stent
Upregulation of genes such as c-myc, which regulates cell division, leads to cellular proliferation. Antisense oligonucleotides have the ability to block critical phases of the smooth muscle cell growth cycle. Inhibition of several cellular protooncogenes has been shown to inhibit smooth muscle cell proliferation in vitro and to reduce neointimal thickening in vivo. C-myc antisense oligonucleotides have also been shown to inhibit both inflammation and extracellular matrix production.
23)
Kipshidze et al. 24) reported that an advanced c-myc-eluting PC stent blocked c-myc expression, and it significantly inhibited myointimal hyperplasia; further, this style of stent allowed for complete reendothelialization and a proper healing response in the porcine coronary model. However, the first clinical experience using the catheter-based local delivery of c-myc antisenseoligonucleotides was disappointing.
25)
Stents eluting antithrombosis agents
Vessel injury with the resulting platelet aggregation and thrombus formation plays a prominent role in the development of restenosis. 26) Antithrombotic pharmacological approaches to inhibit restenosis, however, have proven ineffective.
Nitric oxide and glycoprotein IIb/IIIa inhibitors have been used as stent coatings, but their efficacy has yet to be demonstrated.
27)
Platelet glycoprotein IIb/IIIa inhibitor-eluting stent Platelet activation and aggregation induces arterial thrombosis and this plays a pivotal role in the pathophysiology of acute coronary syndrome. 28) The development of drugs that inhibit fibrinogen binding to the platelet glycoprotein IIb/IIIa receptor has expanded the therapeutic options for treating thrombotic disorders. 29) Abciximab is a potent inhibitor that blocks the final pathway of platelet aggregation and this drug decreases the short-term and long-term event rates after percutaneous coronary intervention. [30] [31] [32] [33] Besides its blocking effect for platelet aggregation, abciximab reacts to CD11b/ CD18 of vascular endothelial cells and macrophages, and it inhibits the inflammatory reaction and proliferation of vascular smooth muscle cells. [34] [35] [36] [37] The possible mechanisms responsible for inhibition of neointimal hyperplasia by abciximab may be this drug's anti-platelet, anti-inflammatory, anti-proliferative, and pro-healing actions. , respectively(p=0.001). They concluded that the abciximab stent was a feasible treatment and it produced a significant inhibition of neointimal hyperplasia, and it also showed a potential therapeutic benefit in the prevention of stent restenosis.
The major advantages of the abciximab-coated stent may be its safety in the thrombus-burden lesions of patients with acute coronary syndrome, the possibility of using it to deliver a short course of anti-platelet therapy and its effectiveness in diabetic patients. We are currently conducting a clinical study using abciximab-coated in patients with acute myocardial infarction.
Hirudin/iloprost-eluting stent
A combination of hirudin and iloprost were blended with a polylactic acid polymer in a homogeneous thin layer and this was loaded onto a stent. While the iloprost was slowly released by the breakdown of the polymer, about 60% of the hirudin was eluted in the first 24 hours. 39) Decreased neointimal formation was observed in sheep and pig injury models that were treated with this antithrombotic-eluting stent, but the clinical data are still pending.
Stents eluting extracellular matrix modulators
The extracellular matrix constitutes a major component of 
Stents eluting prohealing agents
The promotion of healing in the vascular endothelium may be a more natural, and consequently, a safer approach for the prevention of restenosis. Endothelial denudation and dysfunction are common at the site of endovascular interventions and this has been associated with vessel thrombosis and restenosis. 42) In addition, delayed reendothelialization has been associated with the late side effects of potent antiproliferative therapies like radiation therapy. 43) The immediate restoration of endothelial function might abort the initiation of restenosis.
Endothelial cell seeding has been proposed as the ultimate method to assure immediate stent endothelialization, 44) 
Estradiol-eluting stents
Estradiol may improve vascular healing, reduce the smooth muscle cell migration and proliferation, and promote local angiogenesis. 45) Recently, estradiol-eluting phosphorylcholinecoated stents(Abbott/Biocompatibles) implanted into porcine coronary arteries reduced the neointimal hyperplasia by 40% compared with the control stents. 46) EASTER(Estrogen and Stent to Eliminate Restenosis) 47) was a single-center feasibility study that tested 17-β-est- 
Anti-oxidant stents
Carvedilol has an activity to inhibit smooth muscle cell proliferation and migration, and it also has an anti-oxidation effect. Probucol has a vascular protecting activity and it reduced stent restenosis by improving the lumen dimension at the stent placement site. Carvedilol is a neurohumoral antagonist with multiple actions. It was originally discovered as a beta-adrenoreceptor antagonist. However, subsequent research has revealed that this agent possessed potent antioxidant and free radical scavenger properties. In addition, carvedilol inhibits the vascular SMC proliferation induced by a broad group of mitogens such as platelet derived growth factor (PDGF), fibroblast growth factor(FGF), endothelin-1, serum and thrombin, and it produced 84% suppression of neointimal hyperplasia in a rat carotid injury model. The antimitogenic action of carvedilol on vascular smooth muscle has recently been proven to be due to the inhibition of mitogen-activated protein kinase activity and it was also due to its regulation of cell cycle progression. 48) Carvedilol is highly lipophilic, which promotes a rapid cellular uptake, and a stent containing carvedilol may achieve a high local concentration in vessel walls when it is placed in contact with the walls. Since probucol had been discovered as an antioxidizing agent, it has been developed and sold as a lipid-lowering agent. It is an anti-oxidant and reduces restenosis after coronary argioplasty, and has recently been identified as a vascular protectant. 49) BiodivYsio phosphorylcholine-coated stents were dip-coated with carvedilol(5 mg/mL) and probucol(50 mg/mL) by immersing the stents in methanolic carvedilol and probucol solution, respectively. The stents were deployed in pigs and histopathologic analysis was done 4 weeks later. On histomorphometry, the neointimal area decreased by 42% and the lumen area increased by 20%, resulting in a 43% reduction of the area of stenosis in the carvedilol-coated stent groups compared with the control stent groups. For the probucolcoated stent, the lumen area, the neointimal area, and the stenosis area were not significantly different compared with control stents. There were less proliferating nuclear cell antigen-positive cells in the carvedilol-coated stent compared with the control stent and the probucol stent. The carvedilol-coated stent, but not a probucol-coated stent, inhibits neointimal hyperplasia in a porcine stent restenosis model. 50) We are conducting clinical trials using carvedilol loaded stents in our cardiac catheterization laboratory.
Conclusion
In our animal catheterization laboratory, we are developing a new generation of DESs by using double coating technology or by using natural polymers to overcome the problem of polymer-mediated thrombosis or inflammation, and also to enhance healing after stenting.
Future generations of stents will likely be engineered for optimally delivering drugs to specific lesions. Moreover, refining the bare metal stent platform will continue for enhancing the acute procedural success. Furthermore, it is likely that novel polymer materials and pharmacologic agents will be tested for their biological activity on specific disease states and/or on various vascular systems.
